anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clinical studies indicate that more than 80% of patients suffer from surgical-related pain in the first few days after major laparotomy or laparoscopic abdominal surgery and about 10% of these patients may develop chronic postoperative pain (CPSP), which can last up to several years after surgery. One of the major risk factors for developing CPSP is inadequate management of the acute postoperative pain. Laparoscopic gastric sleeve and bypass surgeries the most common bariatric procedures for weight loss and improved management of metabolic syndromes. Patients may suffer from wound pain or referred pain after laparoscopic bariatric operation. Most importantly, 11.8% of these patients complained surgical-related pain one year after operation, and 8% of them required prolonged use of opioid to control CPSP. However, there are currently lack of clinical practice guidelines or recommendations for prevention of CPSP after laparoscopic abdominal surgery. Although regional block techniques (i.e. truncal block or intrathecal opioid) are considered as effective supplementary analgesic approaches to improve postoperative pain control, parenteral administration of analgesics remain as the mainstay for pain management of laparoscopic abdominal surgery. Nalbuphine is a semi-synthetic opioid that acts as a mixed kappa opioid agonist and mu opioid antagonist, but its clinical applications in relieving acute postoperative pain is limited by the relatively short duration of action of 3-6h. Naldebain® is prodrug of nalbuphine, which was approved by the Taiwan FDA in 2017. Naldebain® is an extended-release dinalbuphine sebacate, and is rapidly hydrolyzed by tissue of plasma esterase to release nalbuphine. A number of clinical studies have shown that single-dose of pre-operative intramuscular administration of Naldebain® provides significantly higher analgesic effect up to 1 week in hemorrhoidectomy and laparotomy surgery with a well-tolerated safety profile. Naldebain® has not been tested in laparoscopic bariatric surgery and its pharmacokinetic profiles in overweight patients are undetermined. Therefore, this PI-initiated randomized, double-blind, placebo-control trial aims to investigate the clinical efficacy of Naldebain® in management of acute postoperative pain in patients receiving laparoscopic gastric sleeve or bypass surgery, and prevention of the development of CPSP after surgery. This study will also analyze the plasma levels of nalbuphine following a single intramuscular injection in obese patients.
Cancer of unknown primary is a class of malignant tumors, histologically identified as metastatic lesions whose primary origin is unknown despite adequate investigations for the primary tumor. Although the prognosis of cancer of unknown primary is generally poor, here, we report our experience with a patient who responded to chemotherapy. The patient was a 78-year-old woman. She had a history of gastric cancer at the age of 76 years. In June of year X-1, she was diagnosed with gastric cancer(tub1>tub2, pT1bN0M0, pStage Ⅰa)and underwent distal gastrectomy. One year after surgery, computed tomography revealed right supraclavicular lymphadenopathy, for which cervical lymphadenectomy was performed. The pathological diagnosis was ductal carcinoma with comedo necrosis and poorly differentiated solid adenocarcinoma that were suggestive of metastases from breast cancer. However, a detailed examination of the mammary glands revealed no mass. Imaging studies led to a diagnosis of cancer of unknown primary. Therefore, chemotherapy, according to the treatment of pancreatic cancer, was planned based on immunostaining, tumor markers, etc. Chemotherapy response evaluation after completing 4 courses demonstrated a partial response; the patient responded to the chemotherapy. We considered that estimating primary lesions from histopathological images, tumor markers, etc., may help determine effective chemotherapy regimens.
AIMS: The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A (TubA), reduces myocardial ischaemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic animals. Diabetes augments the activity of HDAC6 and the generation of tumour necrosis factor alpha (TNF-α) and impairs mitochondrial complex I (mCI). Here, we examined how HDAC6 regulates TNF-α production, mCI activity, mitochondria, and cardiac function in type 1 and type 2 diabetic mice undergoing MIRI.
METHODS AND RESULTS: HDAC6 knockout, streptozotocin-induced type 1 diabetic, and obese type 2 diabetic db/db mice underwent MIRI in vivo or ex vivo in a Langendorff-perfused system. We found that MIRI and diabetes additively augmented myocardial HDAC6 activity and generation of TNF-α, along with cardiac mitochondrial fission, low bioactivity of mCI, and low production of adenosine triphosphate. Importantly, genetic disruption of HDAC6 or TubA decreased TNF-α levels, mitochondrial fission, and myocardial mitochondrial nicotinamide adenine dinucleotide levels in ischaemic/reperfused diabetic mice, concomitant with augmented mCI activity, decreased infarct size, and improved cardiac function. Moreover, HDAC6 knockout or TubA treatment decreased left ventricular dilation and improved cardiac systolic function 28 days after MIRI. H9c2 cardiomyocytes with and without HDAC6 knockdown were subjected to hypoxia/reoxygenation injury in the presence of high glucose. Hypoxia/reoxygenation augmented HDAC6 activity and TNF-α levels and decreased mCI activity. These negative effects were blocked by HDAC6 knockdown.
CONCLUSION: HDAC6 is an essential negative regulator of MIRI in diabetes. Genetic deletion or pharmacologic inhibition of HDAC6 protects the heart from MIRI by limiting TNF-α-induced mitochondrial injury in experimental diabetes.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of benzoxazinedione of the general formula (I)   where R 1  means H or carboxyalkyl-group; R 2  means hydrogen atom or alkyl and R 3  means different acidic groups derivatizable from amino acids, dipeptides and hydrazones, their conjugates with active substance respectively, for example, residues from penicillin order. The proposed compounds are heterocyclic protected derivatives of catechol and they effective against strains of gram-negative microorganisms and used as siderofores. Also, invention discloses a medicinal preparation based on compounds of the formula (I). EFFECT: new compounds indicated above, valuable antibacterial properties. 14 cl, 2 tbl
INTRODUCTION: Amblyopia is generally a unilateral disorder, defined by at least a difference of two lines of visual acuity between both eyes with the best-corrected visual acuity, a decrease in contrast sensitivity, and a decrease in stereopsis. Pattern electroretinogram (PERG) is a noninvasive technique that provides a retinal biopotential and is a highly sensitive indicator of changes in the macular area. Our aim was to evaluate if there are differences in the retinal response of an amblyopic eye compared with a normal eye (NE).
METHODS: We evaluated twenty-four adult volunteers, twelve amblyopes (mean 43.42 ± 12.72 years old), and twelve subjects with NE (mean 35.58 ± 12.85 years old). None of the subjects in the two groups had comorbidities. A complete optometric examination was performed including parameters such as visual acuity (VA) by far and near with ETDRS chart, eye alignment with cover test, and evaluation of retinal cells response with PERG.
RESULTS: The refractive error found in the NE group of subjects had a mean of - 0.95 ± 1.65D, while the amblyopic group showed a mean of - 2.03 ± 4.29D. The VA in amblyopic eyes had a mean of 0.38 ± 0.20 logMAR. Analyzing PERG data, we observed significant differences in the P50-N95 amplitudes of the amblyopic group compared with the NE group (p < 0.0001-amblyopic eye vs. NE; p = 0.039-fellow eye vs. NE).
DISCUSSION: These findings suggest that amblyopic patients may also present other impairments beyond the visual cortex. PERGs seem to be an important complementary examination in the diagnosis of other impairments in amblyopia.
The present invention relates to an externally-applied Chinese medicine preparation for treating gout and a preparation method thereof. An externally-applied emplastrum is prepared from Sichuan phellodendron bark, coptis root, dandelion, achyranthes root and borneol. Compared with the prior art, the present invention has the efficiency of clearing away heat, eliminating swelling, alleviating pain and removing dampness by diuresis. The present invention is used for treating the local rednesss, swelling, heat, pain and other disease symptoms of necks, shoulders, waists, legs, etc. caused by gouty arthritis and aseptic inflammation. The present invention has the advantages of obvious effect, convenient use, small stimulation, no toxic side effect, low price of medicines and good therapeutic effect.
A photoadjuvant immunotherapeutical method includes the steps of providing a phototherapeutical apparatus, comprising a light source, an optical guidance system, and a patient interface; determining a minimal erythema dose; performing phototherapy by irradiating a target surface with the phototherapeutical apparatus; and performing immunotherapy by exposing the irradiated target surface to an antigen. The method can be applied to treat allergic diseases, including allergic rhinitis, rhinoconjunctivitis, asthma, and atopic dermatitis, as well as to treat autoimmune diseases. UVA, UVB and visible light can be used, emitted from a quartz bulb with a small discharge volume. The phototherapy increases the tolerance of a patient's body toward an antigen. During immunotherapy the irradiated target surface can be exposed to a naturally present antigen or to an administered antigen. The method can be used to treat RSA by preventing rejection of the fotus, or to suppress rejection reactions in organ or cell transplantation.
Congestive heart failure (CHF) is a chronic disease that is associated with enormous burden of illness. Patients with CHF have diminished health-related quality of life, and due to the high demand associated with their everyday activities and self-management, there is consequently a burden upon family caregivers. Though exercise is a component of clinical practice guidelines for the management of CHF, previous studies have not examined the interrelationships among changes in exercise capacity, health-related quality of life (HRQL) and important predictor variables such as self-efficacy, as a result of exercise training in CHF patients. Furthermore, research to date has failed to examine whether a hospital-based or a home-based approach to exercise is the best-suited strategy for long-term adoption and benefit from exercise training. Thus, the most important effective approach to, and environment for, exercise training to improve the health and self-management of CHF patients has not yet been determined. This study will address some important gaps in the existing literature related to the benefits of exercise in CHF, specifically how different exercise approaches and strategies contribute to an individual's HRQL and self-efficacy.

This is a prospective, randomized controlled trial using a two-group, repeated measures design. Male and female patients with New York Heart Association (NYHA) Functional Class I-III CHF will be eligible to participate. Participants will be randomized to receive either supervised, hospital-based exercise or monitored home-based exercise. The participants in the study will train for a period of six months and will be reassessed six months following completion of the intervention to assess sustainability of any observed changes.
TYK2 is a non-receptor tyrosine kinase member of the Janus kinase (JAKs) family of protein kinases. The mammalian JAK family consists of four members, TYK2, JAK1, JAK2, and JAK3.  JAK proteins, including TYK2, are integral to cytokine signaling. Disorders associated with TYK2 include autoimmune disorder, inflammatory disorder, proliferative disorder, endocrine disorder, neurological disorder, and disorder associated with transplantation.  The present invention provides compounds exemplified by fommla I, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders. (see formula I)
Ganglioglioma (GG) with anaplasia (anaplastic ganglioglioma) is a rare and controversial diagnosis. When present, anaplasia involves the glial component of the tumor, either at presentation or at recurrence. To date, most published cases lack molecular characterization. We describe the histologic and molecular features of 3 patients presenting with BRAF p. V600E-mutant GG (CNS WHO grade 1) with high-grade glial transformation at recurrence. The tumors occurred in pediatric patients (age 9-16 years) with time to recurrence from 20 months to 7 years. At presentation, each tumor was low-grade, with a BRAFV600E-positive ganglion cell component and a glial component resembling pleomorphic xanthoastrocytoma (PXA) or fibrillary astrocytoma. At recurrence, tumors resembled anaplastic PXA or high-grade astrocytomas without neuronal differentiation. CDKN2A homozygous deletion (HD) was absent in all primary tumors. At recurrence, 2 cases acquired CDKN2A HD; the third case showed loss of p16 and MTAP immunoexpression, but no CDKN2A/B HD or mutation was identified. By DNA methylation profiling, all primary and recurrent tumors either grouped or definitely matched to different methylation classes. Our findings indicate that malignant progression of the glial component can occur in GG and suggest that CDKN2A/B inactivation plays a significant role in this process.
(SEE TABLE BELOW)

Carbamazepine suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of a patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs (see PRECAUTIONS, Drug Interactions). Because the extent to which this occurs with other liquid medications is not known, carbamazepine suspension should not be administered simultaneously with other liquid medications or diluents.

Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.

Since a given dose of carbamazepine suspension will produce higher peak levels than the same dose given as the tablet, it is recommended to start with low doses (children 6 to 12 years: ½ teaspoon (four times a day) and to increase slowly to avoid unwanted side effects.

Conversion of patients from oral carbamazepine tablets to carbamazepine suspension: Patients should be converted by administering the same number of mg per day in smaller, more frequent doses (i.e., twice a day tablets to three times a day suspension).

Carbamazepine extended-release tablets is an extended-release formulation for twice-a-day administration. When converting patients from carbamazepine conventional tablets to carbamazepine extended-release tablets, the same total daily mg dose of carbamazepine extended-release tablets should be administered. Carbamazepine extended-release tablets must be swallowed whole and never crushed or chewed. Carbamazepine extended-release tablets should be inspected for chips or cracks. Damaged tablets should not be consumed.
The intervention was delivered via a teen MBSR workbook and online communication across the 10-week intervention period. Participants were assigned weekly readings and activities from an MBSR workbook for teens. Topics included understanding stress, introduction to mindfulness, mindful eating and other mindfulness-based intervention principles and were recommended to be completed daily. Mindfulness-based exercises were either self-led per instructions provided in the workbook or to be completed using an audio recording directing participants' behaviors during the exercise.
Patients receive enzalutamide PO QD alone on days 1-28. Patients then receive enzalutamide PO QD on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To erase a solid powder cosmetic excellent in spreadability and finished gloss feeling, free from causing a so-called caking phenomenon which solidifies a surface when it is rubbed with a small utensil such as a mat, a chip, or the like, and having excellent falling strength. SOLUTION: The solid powder cosmetic contains a component (a) of >=50 mass % of a flaky powder, a component (b) of polytetrafluoroethylene powder and a component (c) of a spherical powder. Further, the solid powder cosmetic contains an oil as the component (d). Further, the solid powder cosmetic has the content of the component (d) of 1-5 mass. Furthermore, the solid powder cosmetic has the content of the component (d) of 15-30 mass %. Further, any one of the above solid powder cosmetics contains a powdery wax as a component (e).
This group will receive 12 daily individual sessions of CPT at the National Ability Center in Park City, Utah. They will also participate in daily recreational activities.
MPM participants who are on the standard of care watch and wait approach i.e. immediate treatment not suitable. Participants will have follow-up for 2 years (3 monthly in year 1, 4 monthly in year 2).
Patients with severe lupus nephritis will be enrolled and received pulse methylprednisolone at a dose of 1.5 to 3.0g, followed by intravenous belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks thereafter. Multitarget therapy will be also administered during the induction phase. Induction therapy will last for 24 weeks.
In this study, it was aimed to compare the effects of exercise therapy, kinesiology taping and high-intensity laser therapy on pain, muscle strength and functional status in patients with LE. Patients who applied to the outpatient clinic of the Sadi Konuk Training and Research Hospital Physical Medicine and Rehabilitation clinic due to elbow pain and were diagnosed with unilateral LE will be included. The study was planned as randomized, prospective and controlled. Patients will be randomized using a random (randomized) numbers table and distributed equally to the groups. Only exercise will be applied to the first group, high-intensity laser therapy and exercise to the second group, and kinesiology taping and exercise treatments to the third group. Sixty people will be included in the study. Patients will be evaluated before treatment, immediately after treatment, and at 4 weeks post-treatment. In the evaluation of the patients, the severity of pain during rest and activity measured with the Visual Analogue Scale (VAS), Quick Disability of the Arm, Shoulder and Hand (QuickDASH), Patient Based Lateral Epicondylitis Evaluation Test - Patient Rated Tennis Elbow Evaluation (PRTEE), Jamar' Hand grip strength will be evaluated with the hand dynamometer.
All CT Lung Cancer Screening patients at LHMC from January 1st, 2012 to September 30th, 2014 with an in-network PCP that had baseline CT scans will be scored. A subset of these patients with T4 screening scans will be scored for progression.
Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).
A network system and a method are disclosed for accessing functionalities or medical data within the framework of a diagnostic findings process. An on-premises server farm, a data center and a plurality of mobile terminal devices are provided for that purpose. The on-premises system is connected to the data center via a local network connection. The mobile network devices are connected to the data center via a mobile communications connection. The data center is a virtualization of the local on-premises server farm. The mobile communications connection to the data exchange is activated as soon as the mobile device leaves the transmit and/or receive range of the respective hospital (off-premises).
PROBLEM TO BE SOLVED: To provide a pigmentation inhibitor comprising an extracted ingredient of Allium cepa dried in the presence of light with water and/or a lower alcohol as an active ingredient and a skin care preparation inhibiting the creation of pigmentation. SOLUTION: This pigmentation inhibitor comprises the extracted ingredient of the Allium cepa dried in the presence of light with water and/or the lower alcohol. The pigmentation inhibitor is produced from a scale of the Allium cepa dried in the presence of light such as natural sunlight or artificial sunlight as a material. The melting point thereof is preferably 285-295 deg.C. The excellent skin care preparation inhibiting the pigmentation can be obtained by formulating the pigmentation inhibitor. The skin care preparation inhibiting the pigmentation and having better effects can be provided by further formulating one or more kinds selected from ascorbic acid, liquiritin, hydroquinone, ellagic acid, kojic acid and derivatives thereof, Rucinol (R), a placental extract liquid and an extract from Matricaria chamomilla therewith.
The invention discloses a Chinese medicinal Chinese angelica-astragalus body-strengthening and immunity-enhancing powder and vaccine combination chicken raising technology. In the technology, Chinese angelica-astragalus body-strengthening and immunity-enhancing powder prepared from Chinese herbal medicines is combined with a vaccine, thereby making use of local Chinese medicinal material resources, enhancing the immunity of livestock, protecting the valence of the vaccine, preventing diseases and promoting the growth of livestock. A formula of the Chinese angelica-astragalus body-strengthening and immunity-enhancing powder comprises 100g of Chinese angelica, 100g of astragalus, 60g of dangshen, 60g of large-head atractylodes rhizome, 60g of cassia bark, 60g of indian buead, 40g of white paeony root, 40g of prepared rehmannia rhizome, 30g of Szechuan lovage rhizome, 40g of kudzuvine root and 15g of liquoric root. The raw materials are mixed and ground into powder, and the powder is mixed with a feed during use of the vaccine. The mixture is taken once every day for three days. Each chick of 1-30 days is fed by 0.3g each time, each chick of 30-60 days is fed by 0.5g each time, each chick of 60-90 days is fed by 0.8g each time, and each adult chick is fed by 1g each time. The technology can be used for increasing the laying rate of laying hens and increasing the contents of trace elements and vitamins. A meat product produced with the technology is fresh and tender in texture, and is good in palatability.
CLL is an incurable disease with current therapies. Modern chemoimmunotherapies, including combinations of rituximab and purine nucleoside analogues (fludarabine, cladribine, and pentostatin), offer the possibility for improved survival, but all patients will eventually relapse. Patients with relapsed or refractory disease will only experience diminishing benefits with additional lines of therapy. In addition, patients with high-risk CLL have poor responses to even first-line therapies. Lenalidomide and dasatinib have non-overlapping proposed mechanisms of action. Single agent phase II studies with lenalidomide and dasatinib have demonstrated responses in heavily pretreated and high-risk patients. For these reasons, we propose to treat patients with relapsed and/or refractory CLL to purine nucleoside analogue therapy with combination lenalidomide and dasatinib.